- Home
- BOW vs COLL Comparison
BOW vs COLL Comparison
Compare BOW & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BOW
- COLL
- Stock Information
- Founded
- BOW 2020
- COLL 2002
- Country
- BOW United States
- COLL United States
- Employees
- BOW N/A
- COLL N/A
- Industry
- BOW Property-Casualty Insurers
- COLL Biotechnology: Pharmaceutical Preparations
- Sector
- BOW Finance
- COLL Health Care
- Exchange
- BOW Nasdaq
- COLL Nasdaq
- Market Cap
- BOW 1.2B
- COLL 958.8M
- IPO Year
- BOW 2024
- COLL 2015
- Fundamental
- Price
- BOW $34.79
- COLL $30.90
- Analyst Decision
- BOW Buy
- COLL Strong Buy
- Analyst Count
- BOW 6
- COLL 4
- Target Price
- BOW $39.67
- COLL $43.75
- AVG Volume (30 Days)
- BOW 226.3K
- COLL 291.8K
- Earning Date
- BOW 08-05-2025
- COLL 08-07-2025
- Dividend Yield
- BOW N/A
- COLL N/A
- EPS Growth
- BOW 18.99
- COLL N/A
- EPS
- BOW 1.33
- COLL 1.25
- Revenue
- BOW $457,704,000.00
- COLL $664,283,000.00
- Revenue This Year
- BOW $22.94
- COLL $20.04
- Revenue Next Year
- BOW $20.42
- COLL $3.98
- P/E Ratio
- BOW $26.13
- COLL $24.77
- Revenue Growth
- BOW 45.29
- COLL 17.17
- 52 Week Low
- BOW $24.61
- COLL $23.23
- 52 Week High
- BOW $42.29
- COLL $42.29
- Technical
- Relative Strength Index (RSI)
- BOW N/A
- COLL 63.50
- Support Level
- BOW N/A
- COLL $29.82
- Resistance Level
- BOW N/A
- COLL $30.83
- Average True Range (ATR)
- BOW 0.00
- COLL 0.81
- MACD
- BOW 0.00
- COLL 0.06
- Stochastic Oscillator
- BOW 0.00
- COLL 62.15
About BOW Bowhead Specialty Holdings Inc. Common Stock
Bowhead Specialty Holdings Inc offers commercial specialty property and casualty insurance products. The company offers underwriting solutions to various businesses across four underwriting divisions, which include Casualty, Professional Liability, Healthcare Liability, and Baleen Specialty. A majority of its revenue is generated from the Casualty division which specializes in general liability coverage, which protects a company against liability arising from bodily injury, personal injury or property damage, for risks in the construction, distribution, heavy manufacturing, real estate, public entity and hospitality segments and also considers underwriting risks in a broader range of industries. Geographically, the company operates in the United States.
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.